Teva Pharmaceutical Industries Limited stock price

Teva Pharmaceutical Industries Limited latest news:


  • 09/11/2017 14:31:12

    Cooper Cos. buys Teva IUD line for $1.1 billion

    Teva Pharmaceuticals Industries Ltd. said late Monday it is selling its Paragard IUD product to Cooper Cos. for $1.1 billion cash. Paraguard had sales of about $168 million for the 12 months ending June 30. The deal includes Teva's plant in Buffalo, N.Y., which makes the Paragard. The deal is expected to close by the end of the year. Teva said it will continue to divest the remaining assets in its women's health business, and in its oncology and pain relief businesses in Europe. Cooper said it expects the deal to add 70 cents to 75 cents a share to earnings in the first year. U.S.-traded Teva shares rose 1.1% to $18.72 after hours, while Cooper shares gained 0.2% to $254. On Monday, Teva shares had their biggest one-day gain since 1984 following the naming of a new chief executive.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 12:50:08

    Drugmaker Teva hires new CEO to restore its health

    Teva Pharmaceutical Industries Ltd names H Lundbeck A/S Chief Executive Kare Schultz as its new CEO and president, as it struggles with heavy debts and fierce competition for its generic drugs in the United States. Amy Pollock reports Video provided by Reuters        

  • 09/11/2017 11:19:47

    Dow industrials rally 260 points, retake 22,000 level, as worries over Hurricane Irma, North Korea abate

    U.S. stock-index benchmarks jump on Monday, as Hurricane Irma hit Florida with less force than expected and North Korea failed to conduct another nuclear missile test over the weekend, helping to lure investors into buying assets perceived as risky like equities. The Dow Jones Industrial Average traded 262 points, or 1.2%, at 22,060, while the S&P 500 index climbed 1.1% at 2,488, putting the broad-market gauge within range of its intraday high. The Nasdaq Composite Index rallied 1.1% at 6,432, was within range of its all-time closing high. In corporate news, investors awaited the debut of Apple Inc.'s new iPhone 8 on Tuesday. In other corporate news, shares of Teva Pharmaceutical Industries Ltd. were up, after the Israeli drug company on Monday named Lundbeck's Kare Schultz as its new chief executive. Meanwhile, Wall Street was marking the anniversary of 9/11. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 10:42:41

    Dow industrials rally 250 points, retake 22,000 level, as worries over Hurricane Irma, North Korea abate

    U.S. stock-index benchmarks jump on Monday, as Hurricane Irma hit Florida with less force than expected and North Korea failed to conduct another nuclear missile test over the weekend, helping to lure investors into buying assets perceived as risky like equities. The Dow Jones Industrial Average traded 250 points, or 1.2%, at 22,054, while the S&P 500 index climbed 1.1% at 2,487, putting the broad-market gauge within range of its intraday high. The Nasdaq Composite Index rallied 1.1% at 6,432, was within range of its all-time closing high. In corporate news, investors awaited the debut of Apple Inc.'s new iPhone 8 on Tuesday. In other corporate news, shares of Teva Pharmaceutical Industries Ltd. were up, after the Israeli drug company on Monday named Lundbeck's Kare Schultz as its new chief executive. Meanwhile, Wall Street was marking the anniversary of 9/11. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 08:08:13

    Dow industrials rally 200 points, retake 22,000 level, as worries over Hurricane Irma, North Korea abate

    U.S. stock-index benchmarks jumped at the open on Monday, as Hurricane Irma hit Florida with less force than expected and North Korea failed to conduct another nuclear missile test over the weekend, helping to lure investors into buying assets perceived as risky like equities. The Dow Jones Industrial Average opened up 201 points, or 0.9%, at 22,010, while the S&P 500 index climbed 0.9% at 2,483, putting the broad-market gauge within range of its closing high. The Nasdaq Composite Index rallied 1.2% at 6,438, also within range of an all-time closing high. In corporate news, investors awaited the debut of Apple Inc.'s new iPhone 8 on Tuesday. In other corporate news, shares of Teva Pharmaceutical Industries Ltd. were up, after the Israeli drug company on Monday named Lundbeck's Kare Schultz as its new chief executive. Meanwhile, Wall Street was marking the anniversary of 9/11. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 07:46:16

    Dow industrials rally nearly 200 points as worries over Hurricane Irma, North Korea abate

    U.S. stock-index benchmarks jumped at the open on Monday, as Hurricane Irma hit Florida with less force than expected and North Korea failed to conduct another nuclear missile test over the weekend, helping to lure investors into buying assets perceived as risky like equities. The Dow Jones Industrial Average opened up 190 points, or 0.9%, at 21,986, while the S&P 500 index climbed 0.8% at 2,481, putting the broad-market gauge within range of its closing high. The Nasdaq Composite Index rallied 1.1% at 6,432, also within range of an all-time closing high. In corporate news, investors awaited the debut of Apple Inc.'s new iPhone 8 on Tuesday. In other corporate news, shares of Teva Pharmaceutical Industries Ltd. were up, after the Israeli drug company on Monday named Lundbeck's Kare Schultz as its new chief executive. Meanwhile, Wall Street was marking the anniversary of 9/11. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/08/2017 12:08:06

    Allergan $13.75 mln agreement with Saint Regis Mohawk Tribe a play to protect key dry eye product

    Allergan PLC shares rose 1.8% in heavy Friday afternoon trade on news of an unorthodox agreement the company has made with the Saint Regis Mohawk Tribe that could protect patents on a key Allergan dry eye product, Restasis. Under the agreement, the Saint Regis Mohawk Tribe now owns patents on Restasis -- which are expected to expire at the end of August 2024 -- and has granted Allergan exclusive licenses on the product. The Saint Regis Mohawk Tribe is filing to dismiss patent challenges under the U.S. Patent and Trade Office's inter partes review process "based on their sovereign immunity from IPR challenges," Allergan said, although the agreement does not affect recent patent litigation in a Texas federal court. Teva Pharmaceutical Industries Ltd. , Mylan NV and Akorn Inc. have all filed IPR challenges related to Restasis. Allergan will pay the Saint Regis Mohawk Tribe $13.75 million upfront and $15 million in annual royalties; an Allergan spokesperson said the latter is for commercial rights to Restasis. The Saint Regis Mohawk Tribe and its lawyer approached Allergan about the agreement, according to a Friday Allergan statement, and there is case law precedent of universities using this approach. The Allergan agreement is "part of our overall economic diversification strategy," the Saint Regis Mohawk Tribal Council said in a statement. "We realize that we cannot depend solely on casino revenues and, in order for us to be self-reliant, we must enter into diverse business sectors to address the chronically unmet needs of the Akwesasne community; such as housing, employment, education, healthcare, cultural and language preservation." Allergan shares have lifted 1.2% over the last three months, compared to a 1.2% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/18/2017 11:41:25

    BRIEF-Teva announces exclusive launch of generic Axiron® in United States

    Teva Pharmaceutical Industries Ltd(TEVA) : * Teva announces exclusive launch of generic Axiron® in the United States. * Teva Pharmaceutical Industries Ltd (TEVA) says launch of generic Axiron topical solution CIII, 30 mg/1.5 ml, in U.S. Source text for Eikon: Further company coverage:

  • 08/17/2017 10:59:47

    Reps. Cummings, Welch to launch investigation into multiple sclerosis drug prices

    Rep. Elijah Cummings (D-Md.) and Rep. Peter Welch (D-Vt.) said Thursday morning that they are launching an investigation into multiple sclerosis drug prices, and have sent letters to seven pharmaceutical companies about their pricing strategies. Letters were sent to Bayer AG , Biogen Inc. , Merck & Co.'s EMD Serono, Novartis AG , Sanofi SA , Teva Pharmaceutical Industries Ltd. and Roche Holding AG . Biogen shares declined 2.9% in heavy midday trade and Teva shares declined 1.1% in moderate trade. The lawmakers asked for information to evaluate multiple sclerosis drugs' "substantial price increases, including information about corporate profits and expenses and documents concerning pricing strategies, patient assistance programs, and drug distribution systems," and requested a response by the end of the month. The average price of a multiple sclerosis disease-modifying therapy rose from $16,000 in 2004 to about $84,000 in 2017, according to the National Multiple Sclerosis Society (the numbers refer to average wholesale price, which does not reflect often-substantial discounts and rebates). Prices for drugs sold by the seven drugmakers have increased by as much as 1,002% since 2012, according to information from the National Multiple Sclerosis Society cited by the two representatives. The lawmakers said that their letter referred to an American Academy of Neurology study that found "some drug companies appear to be increasing their prices and setting new, higher prices in lockstep in competitors," which may reflect a phenomenon called "shadow pricing" in which companies respond to eachothers' price increases. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/14/2017 15:26:44

    Tepper's Appaloosa dumps Snap Inc., stake, loads up on tech, health care

    David Tepper's hedge fund Appaloosa Management unloaded its position in Snapchat-parent Snap Inc., and disclosed increases in the tech and health-care sectors at the end of the second quarter. As of June 30, Tepper's fund showed that his fund dumped 100,000 shares of of Snap Inc. , which has lost more than a third of its value since it debuted as a public entity in early March. Tepper had been one of a number of prominent investors who had vocally expressed support of the social-messaging company. On Monday, Snap's shares were among the most active, gaining about 6.5% to start the week. Elsewhere, Appaloosa showed new positions in the PowerShares QQQ Trust Series 1 , which mimics the technology laden Nasdaq-100 , purchasing 1.8 million shares of the so-called QQQs, valued at $249 million, representing about 3.7% of his overall portfolio, according to data from research provider Whalewisdom.com. The fund also more than doubled its Apple Inc. position to 625,000 shares worth about $90 million and those of Altaba Inc. , which he boosted to 5.1 million shares valued at $280 million. Appaloosa showed a fresh stake in Alibaba Group Holding Limited , scooping up 3.6 million shares worth $520 million. Tepper's investment vehicle added a new position in exchange-traded IBB , a prominent ETF tracking the biotech sector, and SPDR S&P Biotech ETF , which closely mimics the S&P 500's health-care sector. Tepper's firm bought 235,000 shares of IBB worth about $73 million and 330,000 shares of XBI valued at $34 million, as of the end of June. In other sales, Tepper & Co. unloaded all of its position in Teva Pharmaceutical Industries , Energy Transfer Partners L.P. and Pfizer Inc. among others. Related: Active-managers have a new favorite toolMarket Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/14/2017 15:14:19

    Tepper's Appaloosa dumps Snap Inc. stake, loads up on tech, health care

    David Tepper's hedge fund Appaloosa Management unloaded its position in Snapchat-parent Snap Inc., and disclosed increases in the tech and health-care sectors at the end of the second quarter. As of June 30, Tepper's fund showed that his fund dumped 100,000 shares of of Snap Inc. , which has lost more than a third of its value since it debuted as a public entity in early March. Tepper had been one of a number of prominent investors who had vocally expressed support of the social-messaging company. On Monday, Snap's shares were among the most active, gaining about 6.5% to start the week. Elsewhere, Appaloosa showed new positions in the PowerShares QQQ Trust Series 1 , which mimics the technology laden Nasdaq-100 , purchasing 1.8 million shares of the so-called QQQs, valued at $249 million, representing about 3.7% of his overall portfolio, according to data from research provider Whalewisdom.com. The fund also more than doubled its Apple Inc. position to 625,000 shares worth about $90 million and those of Altaba Inc. , which he boosted to 5.1 million shares valued at $280 million. Appaloosa showed a fresh stake in Alibaba Group Holding Limited , scooping up 3.6 million shares worth $520 million. Tepper's investment vehicle added a new position in exchange-traded IBB , a prominent ETF tracking the biotech sector, and SPDR S&P Biotech ETF , which closely mimics the S&P 500's health-care sector. Tepper's firm bought 235,000 shares of IBB worth about $73 million and 330,000 shares of XBI valued at $34 million, as of the end of June. In other sales, Tepper & Co. unloaded all of its position in Teva Pharmaceutical Industries , Energy Transfer Partners L.P. and Pfizer Inc. among others.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/07/2017 10:10:36

    Teva's stock keeps plunging on heavy volume after Morgan Stanley downgrade

    Shares of Teva Pharmaceutical Industries Ltd. tumbled 8% in morning trade Monday on heavy volume, putting them on track to close at a 14-year low, as Morgan Stanley turned bearish on the generic drug maker in the aftermath of disappointing results. Volume ballooned to 39.1 million shares, which was more than triple the full-day average, and enough to make it the most actively traded stock on the major U.S. exchanges. The stock was headed for an eighth straight loss to the lowest close since March 13, 2003, highlighted by 39% plunge the past three sessions after the company missed profit expectations and cut its outlook, citing accelerated price erosion and decreased volume in its U.S. generics business. On Monday, Morgan Stanley analyst David Risinger cut his rating to underweight from equal weight, and slashed his stock price target to $16 from $36, saying he had underappreciated the risk of generics pricing pressure to Teva's earnings. The stock has plummeted 48% year to date, while the SPDR S&P Pharmaceuticals ETF has gained 5.9% and the S&P 500 has advanced 11%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/03/2017 14:33:46

    Teva and 3D Systems slide while Kellogg and Tesla jump

    Teva Pharmaceutical Industries and 3D Systems tumble while Kellogg and Tesla trade higher

  • 08/03/2017 09:12:21

    Teva's stock plunges on heavy volume after profit miss and slashed outlook

    Shares of Teva Pharmaceuticals Industries Ltd. plunged 10.4% in active premarket trade Thursday, after the drug maker missed fiscal second-quarter profit expectations and slashed its full-year outlook. Volume of 1.5 million shares made the stock the most actively traded ahead of the open. The net loss for the quarter to June 30 was $6.04 billion, or $5.94 a share, after a profit of $188 million, or 20 cents a share, in the same period a year ago.

  • 08/03/2017 09:12:21

    AmerisourceBergen stock plummets 9% alongside other companies affected by negative generic price trends

    AmerisourceBergen Corp.(ABC) shares plummeted 9% in extremely heavy morning trade Thursday after the company reported third-quarter profit beat but revenue miss. Shares of the drug distributor fell alongside other companies affected by generic price deflation on Thursday, after Teva Pharmaceutical Industries Ltd. (TEVA) reported generics revenue that was below expectations and cut its 2017 adjusted EPS outlook. AmerisourceBergen (ABC) said on its earnings call that generic...

  • 07/12/2017 13:18:57

    AstraZeneca's CEO Soriot to join Israeli drugs company Teva-report

    Israel-based Teva Pharmaceutical Industries (TEVA) will name AstraZeneca (AZN) chief executive Pascal Soriot as its next CEO, the Calcalist financial news website said on Wednesday. Soriot has met with Teva representatives and expressed his agreement to serve as its next CEO.

  • More trends:

    Texas Pacific Land TrustTPL | Textainer Group Holdings LimitedTGH | Textron Inc.TXT | Textura CorporationTXTR | Thai FundTTF | The AES CorporationAES | The AES CorporationAES^C | The Blackstone Group L.P.BX | The Charles Schwab CorporationSCHW | The Charles Schwab CorporationSCHW^B |